Prostatype Genomics AB Capital Reinvestment Ratio
Latest as of June 2020:
0.06x
Prostatype Genomics AB capital reinvestment ratio. Prostatype Genomics AB (PROGEN) has a Capital Reinvestment Ratio of 0.06x as of June 2020, meaning it reinvests 0% of its operating cash flow (Skr5.63 Million) in capital expenditures (Skr361.71K). Check PROGEN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
0.06x
Capex / Operating Cash Flow
Operating Cash Flow
Skr5.63 Million
SEK
Capital Expenditures
Skr361.71K
SEK
Data as of
Jun 2020
Most recent filing
Prostatype Genomics AB Capital Reinvestment Ratio by Year (None–None)
Prostatype Genomics AB capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see cash flow conversion of Prostatype Genomics AB.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow